Small molecule inhibitors targeting LRRK2 kinase have demonstrated neuroprotective effects in both preclinical and clinical translational studies of PD, making them a promising therapeutic strategy for the disease (Kingwell, 2022). Here, LRRK2 is linked to Parkinson disease.